Full-Time

Manager – GRC Technology

Metrics and Automation

Posted on 9/8/2026

Deadline 9/23/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$99.2k - $165.4k/yr

+ 12.5% target bonus + Share-based long-term incentive program

No H1B Sponsorship

New York, NY, USA

Hybrid

Two to three days in the assigned Pfizer office per week, or as needed. Travel is required less than 20% domestically and/or internationally.

Bachelor's, Master's, PhD, Associate's

Category
Cybersecurity (1)
Required Skills
Power BI
Agile
Data Visualization
Data Engineering
Cybersecurity
Tableau
Risk Management

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A bachelor's degree with at least 4 years of experience, or a master's degree with at least 2 years of experience, or a PhD with 0+ years of experience, or an associate's degree with 8 years of experience, or a high school diploma or equivalent with 10 years of relevant experience.
  • At least 4 years of experience in information technology or cybersecurity.
  • Experience with GRC platforms, reporting, and workflow automation.
  • Ability to design metrics and dashboards that support executive decision-making.
  • Experience operating in a highly regulated, matrixed enterprise environment.
  • Experience working in an agile environment.
  • Ability to manage multiple priorities and work with cross-functional teams.
  • Strong stakeholder management, communication, and executive-level presentation skills.
Responsibilities
  • Define and execute the technology roadmap for Cyber GRC tooling in alignment with enterprise risk priorities, regulatory requirements, and operating model maturity.
  • Partner with IT and platform teams on system upgrades, integrations, data feeds, and configuration enhancements.
  • Define and govern Cyber GRC metrics, key performance indicators, and key risk indicators.
  • Ensure metrics are risk-aligned, standardized, and decision-useful rather than activity-based.
  • Develop executive-level dashboards for senior leadership, risk committees, and governance forums.
  • Identify and drive automation opportunities across Cyber GRC processes to reduce manual effort, improve data quality, and increase consistency.
  • Lead implementation of workflow automation, approvals, notifications, evidence collection, and reporting capabilities.
  • Ensure alignment between GRC data and enterprise data standards.
  • Partner with data and analytics teams to enable scalable reporting solutions, including business intelligence tools, dashboards, and automation pipelines.
  • Serve as a key partner to Cybersecurity leadership, IT, Infrastructure, Cloud Services, Privacy, Quality, and Internal Audit.
  • Translate stakeholder needs into practical technology and reporting solutions.
  • Influence adoption and consistent use of GRC platforms across global teams.
  • Contribute during internal audits, external audits, and regulatory inspections by ensuring metrics and system outputs are defensible and traceable.
Desired Qualifications
  • A bachelor's degree in information technology, cybersecurity, computer science, or a related field.
  • Experience working in the pharmaceutical industry.
  • Professional certifications such as CISSP, CISM, CRISC, CISA, PMP, or similar.
  • Hands-on experience with ServiceNow GRC, Archer, Power BI, Tableau, or similar tools.
  • Experience in large, complex, or regulated environments.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved Pfizer-BioNTech’s XFG COVID vaccine on August 27, 2026 for fall shipping.
  • Pfizer raised 2026 revenue guidance to $60.5 billion-$62.5 billion on August 4, 2026.
  • Padcev and Lorbrena grew in Q2 2026, proving post-Seagen oncology momentum.

What critics are saying

  • Eliquis loses U.S. exclusivity in 2028, opening a rapid generic cliff.
  • Arbutus filed international LNP patent suits on July 16, 2026 against Pfizer-BioNTech.
  • Comirnaty and Paxlovid remain shrinking as FDA narrows eligibility and COVID demand fades.

What makes Pfizer unique

  • Pfizer’s Seagen acquisition gives it a stronger oncology engine than pure-vaccine peers.
  • Eliquis and Vyndaqel diversify revenue beyond COVID, with Q2 2026 growth.
  • Pfizer’s global commercial scale still pushes products through pharmacies, hospitals, and governments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.